Business Wire (Nov 26, 2013)
PR Newswire (Jun 19, 2012)
PR Newswire (Jun 14, 2012)
Oncosec Medical Incorporated develops novel ElectroOncology therapies that combine its proprietary electroporation delivery technology with a chemotherapeutic or novel DNA-based immunotherapeutics. Targeted delivery of these agents is designed to achieve selective destruction of cancerous... More
Tuesday, Oct 87:25 AMOncoSec Medical immunotherapy helps reduce tumors in mice
Tuesday, Oct 87:25 AM| 4 Comments
- OncoSec Medical (ONCS.OB) says that combining ImmunoPulse DNA-based immunotherapy with anti-CTLA4 and anti-PD1 antibodies was effective in reducing tumors in a trial of 40 mice.
- While the mice were treated with ImmunoPulse alone, or in combination with anti-CTLA4, anti-PD1 or both, there was 100% regression of treated lesions in all of the animals, with none dying due to toxicity.
- OncoSec now intends to test various approaches in more aggressive melanoma models with a view to eventually carrying out human trials. (PR)
Monday, Jul 228:58 AM